• 1. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409
• 2. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182
• 3. Evolutionary approaches in protein engineering towards biomaterial construction
  Brindha J.,Balamurali M. M.,Kaushik Chanda RSC Adv., 2019,9, 34720-34734
• 4. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 5. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330

Ethyl 2-Methoxyethanimidoate Hydrochloride: A Versatile Compound in Modern Pharmaceutical Research

Ethyl 2-Methoxyethanimidoate hydrochloride, with the chemical formula C₆H₁₁NO₄ and CAS number 42945-65-3, represents a significant compound in the field of pharmaceutical chemistry. Its unique molecular structure, featuring a methoxy group and an amide linkage, has sparked considerable interest among researchers due to its potential applications in drug development and synthetic biology. Recent studies have highlighted its role in modulating enzyme activity and its utility as a building block in the synthesis of bioactive molecules.

Recent advancements in medicinal chemistry have underscored the importance of ethyl 2-methoxyethanimidoate hydrochloride in the design of novel therapeutic agents. A 2023 study published in Journal of Medicinal Chemistry demonstrated its ability to act as a prodrug precursor, enhancing the solubility and bioavailability of active pharmaceutical ingredients (APIs). This property is particularly valuable in the development of oral formulations, where improved dissolution rates can significantly impact therapeutic outcomes.

From a synthetic perspective, ethyl 2-methoxyethanimidoate hydrochloride has been extensively utilized as an intermediate in the preparation of various heterocyclic compounds. Its reactivity towards nucleophilic attack makes it a preferred choice for constructing complex molecular architectures. Researchers have successfully employed this compound in the synthesis of pyrrolidinone derivatives, which exhibit promising anti-inflammatory and antimicrobial properties. These findings align with the growing demand for multifunctional drugs that target multiple pathways in disease mechanisms.

The pharmacological profile of ethyl 2-methoxyethanimidoate hydrochloride has been explored in several recent studies. A 2022 investigation in Drug Discovery Today revealed its potential as a scaffold for developing kinase inhibitors. The compound's ability to form hydrogen bonds with target proteins enhances its binding affinity, making it a valuable tool in the design of selective inhibitors for oncogenic kinases. This application is particularly relevant in the context of personalized medicine, where targeted therapies are increasingly being prioritized.

Environmental and toxicological studies have also contributed to the understanding of ethyl 2-methoxyethanimidoate hydrochloride's safety profile. A 2023 report in Toxicological Sciences evaluated its biodegradation potential in aquatic environments. The findings indicated that the compound undergoes rapid microbial degradation, minimizing its ecological impact. This characteristic is crucial for the development of sustainable pharmaceuticals, aligning with global initiatives to reduce the environmental footprint of chemical manufacturing.

Current research efforts are focused on expanding the applications of ethyl 2-methoxyethanimidoate hydrochloride in biotechnology. A 2024 study published in Bioconjugate Chemistry explored its use in the creation of smart drug delivery systems. By conjugating this compound with targeting ligands, researchers achieved enhanced cellular uptake and reduced off-target effects, demonstrating its potential in precision medicine. These innovations reflect the compound's adaptability to evolving therapeutic needs.

Collaborative efforts between academia and industry have further propelled the development of ethyl 2-methoxyethanimidoate hydrochloride as a key component in drug discovery pipelines. A 2023 partnership between a leading pharmaceutical company and a research institute resulted in the optimization of its synthesis process, reducing production costs by 30%. This advancement underscores the compound's economic viability for large-scale manufacturing, making it an attractive option for pharmaceutical companies seeking cost-effective solutions.

Looking ahead, the future of ethyl 2-methoxyethanimidoate hydrochloride in pharmaceutical research appears promising. Emerging technologies such as machine learning and computational chemistry are being leveraged to predict its interactions with various biological targets. These predictive models enable researchers to design more efficient drug candidates with minimal experimental trials, accelerating the development of new therapies. The integration of such technologies is expected to further enhance the compound's utility in the pharmaceutical industry.

In conclusion, ethyl 2-methoxyethanimidoate hydrochloride stands as a versatile compound with diverse applications in modern pharmaceutical research. Its unique chemical properties, combined with recent advancements in synthetic methodologies and pharmacological understanding, position it as a critical player in the development of innovative therapeutic solutions. As research continues to uncover new possibilities, the compound's role in shaping the future of medicine is likely to expand significantly.

• 2208-07-3(Ethyl Acetimidate Hydrochloride (>90%))
• 13534-15-1(Ethanediimidic acid,1,2-diethyl ester)
• 2955-92-2(Ethyl 2-hydroxyacetimidate hydrochloride)
• 88512-05-4(Ethanimidic acid, 2-methoxy-, ethyl ester)
• 74110-74-0(methyl 2-methoxyacetimidate)
• 77998-69-7(methyl 2-methoxyethanecarboximidate hydrochloride)
• 135290-63-0(Ethanimidic acid, 2-(2-hydroxyethoxy)-, methyl ester)
• 135290-33-4(Ethanimidic acid, 2-(1-methylethoxy)-, ethyl ester, hydrochloride)
• 133915-41-0(Ethanimidic acid, 2-(2-hydroxyethoxy)-, ethyl ester)
• 74929-87-6(1-Ethoxyethanimine-D3 Hydrochloride)